Last update: 2 April 2020
Frequently asked questions (FAQs)
This document highlights COVID-19 specific considerations in relation to camp and camp-like settings, and is intended to assist in guiding operations where camp/site management5 is being implemented. Although the guidance - structured around questions from the fiel...d - is intended for camp/site managers, UNHCR senior managers/ heads of ooffices, field coordinators and other staff (e.g. programme, protection) should be aware of the guidance and the operational implications in order to provide appropriate support, including to partners implementing camp/site management programmes.
more
Nota científica
24 de abril de 2020
El desarrollo de inmunidad a un patógeno por infección natural es un proceso de varias etapas que suele producirse a lo largo de una o dos semanas. El organismo responde a una infección vírica de forma inmediata a través de una respuesta innata no específ...ica, en la que los macrófagos, los neutrófilos y las células dendríticas frenan el avance del virus y pueden incluso evitar que este provoque síntomas. A esta respuesta no específica le sigue una respuesta adaptativa en la que el organismo genera anticuerpos que se unen específicamente al virus. Estos anticuerpos son las proteínas denominadas inmunoglobulinas. El organismo también genera linfocitos T que reconocen y eliminan las células infectadas por el virus: es lo que se conoce como inmunidad celular. Esta respuesta adaptativa combinada puede eliminar el virus del organismo y, si la respuesta es suficientemente intensa, puede evitar el agravamiento de la enfermedad o la reinfección por el mismo virus. Este proceso se mide a menudo a través de la presencia de anticuerpos en la sangre.
more
Guiding principles for reuse are:
Respirators which have been visibly contaminated (e.g. during procedure at intubated patients, such as suction cleaning of airways, taking probes, extubation attempts, etc.) or are damaged or not fitting, should be discarded and cannot be taken for re-use or de...contamination procedures.
Respirators may be protected by a medical face mask in order to prevent soiling.
Use of new ‘expired respirators’ (manufacturers expiry date) is possible if they were properly stored until use.
more
Mental health and psychosocial considerations during the COVID-19 outbreak
Since March, the COVID-19 pandemic has impacted operations and required a different approach to communication with communities.
UNHCR communication channels have been rapidly enhanced and enlarged to ensure the continued provision of vital health and protection information.
There are indigenous communities at high risk in every country of the region. At stake are the lives of 45 million people who belong to more than 800 indigenous peoples. Of these, some 100 are spread across several countries, around 200 maintain voluntary isolation or are in initial contact, and nea...rly 500 are at risk of disappearing due to their reduced numbers. Due to their lower immune resistance, their lack of access to hospital care and the increasing penetration of extractive activities in their territories, indigenous communities in voluntary isolation or in initial contact are cause for particular concern.
Far from hospitals and the news cameras, indigenous people in Latin American become ill and die without access to the means needed to protect themselves. They face the pandemic in conditions of social exclusion, racism and discrimination, which highlights historical inequalities and extreme precariousness in basic and health services.
more
Rev Méd Hondur, Vol 88, Núm 2, 202
Interim Guidance 8 January 2021
La presente publicación describe la literatura científica revisada sobre las intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019. El Ministerio de Salud solicitó la revisión de la evidencia disponible para nueve intervenciones terapéuticas frente a COVID-...19. Este listado contempla 03 intervenciones que no fueron consideradas en la Revisión Rápida de Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 . Serie Revisión Rápida N° 02-2020, correspondiendo a Ivermectina, Tocilizumab y pulsos de corticoides. En vista del rol potencial de cada intervención en el tratamiento de COVID-19, se plantearon dos respuestas PICO a fin de revisar la evidencia disponible respecto a siete potenciales opciones para tratamiento específico y dos fármacos que se han señalado como terapia adyuvante para frenar la respuesta inflamatoria presentada en COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19.
more
La presente publicación describe un resumen de la evidencia científica disponible sobre el uso de Cloroquina e hidroxicloroquina, así como su profilaxis y tratamiento para COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
Recommendations on the management of diabetes mellitis during the COVID-19 pandemic
The purpose of this document is to provide relevant information and guidelines on
coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the
diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a
primary care context (i.e. community phar...macies and primary healthcare facilities) and in
hospital settings, as well as for pharmacists working as clinical biologists in medical
analysis laboratories, for example, as clinical biologists, and offer a set of references that
may be consulted for more informationstor
more
Guidelines for diagnosis, acute care and post-COVID-19 follow-up for children and adolescents
This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up...date this review and corresponding recommendations as new evidence becomes available.
more
Organización Mundial de la Salud. (2022). Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022.